Several evidences confirm the implication of nuclear PLC signaling in different tumor systems, especially in myelodysplastic syndromes [18,19], but also in breast cancer, melanoma, and pancreatic and colorectal cancers [8]. The gene discussed is HSPG2; the disease is neoplasm.